COVID-19

Study evaluates the effect of long-acting monoclonal antibodies tixagevimab and cilgavimab treating COVID-19 symptoms and viral shedding.

Investigators of the phase 2 study also found a comparable reactogenicity to the individual influenza and COVID-19 vaccines from Novavax or authorized vaccine comparators.

Study shows that the nervous system of individuals experiencing post-COVID-19 fatigue is underactive in 3 key areas.

Investigators found that providing parents with a hypothetical scenario outlining why they should immunize their children against COVID-19 was effective in improving vaccination rates.

The 2022-2023 COVID-19 season did not have a significant surge of COVID-19 like it did early on in the COVID-19 pandemic.

Data from the expanded trial suggests that the NVX-CoV2373 COVID-19 vaccine protects against multiple viral variants.

Neutralizing monoclonal antibody therapies found to improve outcomes for unvaccinated and nonhospital patients at high risk of poor outcome for SARS-CoV-2.

The BCG vaccine was more likely to cause symptomatic or severe COVID-19 in patients that had a preexisting condition, such as heart disease, by 6 months.

Study shows intramuscular injection may improve treatment success by increasing the speed of drug absorption.

Analysis shows that the ratio of neutralizing antibody geometric mean titers in adolescents compared with young adults was 1.5 after vaccination with NVX-CoV2373.

Risk of incident diabetes was markedly higher among males and in those with more severe COVID-19.

The SUNRISE-3 trial is investigating its use in high-risk patients regardless of COVID-19 vaccination status.

Study results indicate a decrease in the exclusion of older adults but no significant change for individuals who are immunocompromised.

All-cause inpatient mortality or discharge to hospice was lower for patients who received dexamethasone within 48 hours of either admission or escalation in oxygen support.

Results of a review show that lessons learned from the pandemic apply to the respiratory syncytial virus.

Worldwide, the human immune system tends to make the same antibodies when targeting viruses, which can modify their structure to avoid detection.

Agency updates emergency use authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccinations, which are no longer authorized for used in the United States.

The data support the use of interventions at home, including frequent handwashing, physical distancing, regular surface disinfection, and wearing a mask.

Emerging evidence suggests that the risk of maternal mortality was more than 10-times greater among those with COVID-19 infection.

41% of patients report moderate-to-severe issues, with Black individuals 3 times more likely to develop these difficulties.

Patients administered anakinra did not meet a study’s primary endpoint of proportion of patients who did not need mechanical ventilation 15 days after starting treatment for severe COVID-19 pneumonia.

The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.

Among those without HIV, the analyses found that respondents with a history of COVID-19 performed worse on processing speed than those who had never had COVID-19.

The disease is the continuation of new symptoms 3 months after the initial SARS-CoV-2 infection and at least lasting 2 months after infection, according to the health organization.

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.